The need for new antimalarial drugs is dire, and this work identifies attractive lead compounds for drug development as well as important probes for dissecting a key antimalarial drug target, the non-mevalonate pathway for isoprenoid biosynthesis. This pathway does not exist in humans, making it an extremely attractive, specific target for antimalarial drug design.
- KeViRx-UVA-ODU Collaborative SBIR Grant funded
- Paul Carlier, Chair of the VaDDC, Receives Grant to Study Promising Antimalarial Drugs
- Norwegian researchers have shown that a phosphatase (PRL-3) inhibitor developed by VaDDC Exec. Comm. member John Lazo might be useful to treat cancer
- Webster Santos, Virginia Tech drug researcher receives $2.2 million NIH grant to further develop “fat burning” molecule
- VaDDC Executive Committee Member, Beth Sharlow Receives Promotion at UVA